The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of Postgraduate Education Studies, Moscow, Russia;...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-05-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-predi-peer-reviewed-article-DDDT |
id |
doaj-084a5e689b81484c82b063dd7653eb8c |
---|---|
record_format |
Article |
spelling |
doaj-084a5e689b81484c82b063dd7653eb8c2020-11-24T22:45:53ZengDove Medical PressDrug Design, Development and Therapy1177-88812018-05-01Volume 121147115638189The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivoSychev DAAshraf GMSvistunov AAMaksimov MLTarasov VVChubarev VNOtdelenov VADenisenko NPBarreto GEAliev GDmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of Postgraduate Education Studies, Moscow, Russia; 2King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 3Sechenov First Moscow State Medical University, Moscow, Russia; 4Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation, Kazan State Medical Academy, Volga Region, Kazan, Russia; 5Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; 6Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 7GALLY International Biomedical Research Consulting LLC, San Antonio, TX, USA; 8School of Health Science and Healthcare Administration, University of Atlanta, Johns Creek, GA, USA; 9Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, Russia Abstract: Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays. Keywords: cytochrome CYP450, drug interaction, drug metabolism, phenotypinghttps://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-predi-peer-reviewed-article-DDDTCytochrome CYP-450Drug interactionDrug metabolismPhenotyping; |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sychev DA Ashraf GM Svistunov AA Maksimov ML Tarasov VV Chubarev VN Otdelenov VA Denisenko NP Barreto GE Aliev G |
spellingShingle |
Sychev DA Ashraf GM Svistunov AA Maksimov ML Tarasov VV Chubarev VN Otdelenov VA Denisenko NP Barreto GE Aliev G The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo Drug Design, Development and Therapy Cytochrome CYP-450 Drug interaction Drug metabolism Phenotyping; |
author_facet |
Sychev DA Ashraf GM Svistunov AA Maksimov ML Tarasov VV Chubarev VN Otdelenov VA Denisenko NP Barreto GE Aliev G |
author_sort |
Sychev DA |
title |
The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo |
title_short |
The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo |
title_full |
The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo |
title_fullStr |
The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo |
title_full_unstemmed |
The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo |
title_sort |
cytochrome p450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2018-05-01 |
description |
Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of Postgraduate Education Studies, Moscow, Russia; 2King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 3Sechenov First Moscow State Medical University, Moscow, Russia; 4Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation, Kazan State Medical Academy, Volga Region, Kazan, Russia; 5Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; 6Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 7GALLY International Biomedical Research Consulting LLC, San Antonio, TX, USA; 8School of Health Science and Healthcare Administration, University of Atlanta, Johns Creek, GA, USA; 9Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, Russia Abstract: Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays. Keywords: cytochrome CYP450, drug interaction, drug metabolism, phenotyping |
topic |
Cytochrome CYP-450 Drug interaction Drug metabolism Phenotyping; |
url |
https://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-predi-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT sychevda thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT ashrafgm thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT svistunovaa thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT maksimovml thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT tarasovvv thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT chubarevvn thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT otdelenovva thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT denisenkonp thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT barretoge thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT alievg thecytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT sychevda cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT ashrafgm cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT svistunovaa cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT maksimovml cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT tarasovvv cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT chubarevvn cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT otdelenovva cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT denisenkonp cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT barretoge cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo AT alievg cytochromep450isoenzymeandsomenewopportunitiesforthepredictionofnegativedruginteractioninvivo |
_version_ |
1725687149560332288 |